Forty-five participants (age range: 19–56 years) that reported current use of both alcohol and cannabis were recruited from the community and enrolled in the study. The structured clinical interview for DSM-V (SCID-5-RV) was administered to every participant in order to ensure a systematic evaluation and accurate diagnosis of substance use disorders48. Interviewers were trained and overseen by a clinical psychologist, and all participants completed the interview process. Participants’ number of symptoms for current alcohol use disorder (AUD) and cannabis use disorder (CUD) were utilized to categorize participants into positive/negative AUD/CUD. Participants also completed the Alcohol Use Disorder Identification Test (AUDIT49) and Cannabis Use Disorder Identification Test (CUDIT-R50), underwent urine drug screens to confirm self-reported recent substance use, and were instructed not to use substances immediately prior to participation in the study. Exclusionary criteria included any diagnosed psychiatric disorder other than substance use disorder, current use of psychiatric medication, any other chronic medical illness affecting CNS function, pregnancy, and presence of any ferrous metal implant (orthodontures, cardiac pacemaker, surgical implants, etc.) which may interfere with the MEG/MRI data acquisition. The institutional
